BrightSpring Health Services (NASDAQ:BTSG) on Friday reported strong first-quarter results and increased its full-year guidance.

The home health care service provider reported first-quarter adjusted earnings of 39 cents per share, beating the analysts' estimate of 31 cents.

Sales jumped 35.6% to $3.61 billion, surpassing the consensus of $3.39 billion. Adjusted EBITDA of $190 million rose 44.8% compared to $131 million a year ago.

BrightSpring Health Services increased its fiscal 2026 sales guidance from $14.45 billion-$15 billion to $14.73 billion-$15.23 billion compared to the consensus of $14.85 billion. Total Adjusted EBITDA is expected to be between $795 million and $825 million. The Amedysis and LHC acquisition is expected to contribute approximately $30 million in Adjusted EBITDA in 2026.

BrightSpring Health shares rose 2% to trade at $53.60 on Monday.

These analysts made changes to their price targets on BrightSpring Health following earnings announcement.

  • BTIG analyst David Larsen maintained BrightSpring Health with a Buy and raised the price target from $55 to $65.
  • BMO Capital analyst Sean Dodge maintained the stock with an Outperform rating and raised the price target from $52 to $60.
  • Stephens & Co. analyst Raj Kumar maintained the stock with an Overweight rating and raised the price target from $53 to $64.
  • Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and raised the price target from $55 to $60.

Considering buying BTSG stock? Here’s what analysts think:

Photo via Shutterstock